Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
Originally on
Life Science Connect · hosted by Ben Comer
The guests
Dr. Adam Rogers, MD
CEO, NervGen; board-certified ophthalmologist; $400M+ exit to J&J with Hemera
Rich Macary
Board Advisor, NervGen; ex-Sarepta VP Business Development
NervGen CEO (board-certified ophthalmologist, $400M+ J&J exit with Hemera) and Board Advisor (ex-Sarepta VP BD) on NVG-291 — the first-ever therapeutic candidate for chronic spinal cord injury.
In this episode
- NVG-291: 35-amino acid neuroreparative peptide entering Phase 3 for SCI
- 825% improvement in hand function; effects persisted 4 weeks after drug stopped
- CSPG inhibition mechanism enabling permanent neuronal rewiring
- DoD funding for TBI, stroke, hearing loss; NASDAQ listing strategy
Listen & watch
Keep listening